Cost-effectiveness of using an extensively hydrolyzed casein formula supplemented with Lactobacillus rhamnosus GG in managing IgE-mediated cow’s milk protein allergy in the UK

Abstract Objective: To estimate the cost-effectiveness of using an extensively hydrolyzed casein formula (eHCF) plus the probiotic Lactobacillus rhamnosus GG (eHCF plus LGG; Nutramigen* LGG®) compared to an eHCF alone as first-line dietary management for Immunoglobulin E (IgE)-mediated cow’s milk protein allergy (CMPA) in the UK. Methods: Decision modelling was undertaken to estimate the probability of IgE-mediated cow’s milk allergic infants being symptom free (i.e. not experiencing urticaria, eczema, asthma or rhinoconjunctivitis) and developing tolerance to cow’s milk by 5 years. The model also estimated the cost (at 2016/2017 prices) of healthcare resource use funded by the UK’s National Health Service (NHS) over 5 years after starting a formula, as well as the relative cost-effectiveness of the two dietary formulae. Results: At 5 years after the start of a formula the probability of being symptom free was estimated to be 0.97 and 0.76 among infants who were originally fed eHCF plus LGG and an eHCF alone, respectively. This encompassed the probability of children being asthma free at 5 years after the start of treatment, which was 0.99 and 0.91 in the eHCF plus LGG and eHCF alone groups, respectively. Additionally, the probability of acquiring tolerance to cow’s milk was estimated to be 0.94 and 0.66 among infants who were originally fed eHCF plus LGG and an eHCF alone, respectively. The estimated total healthcare cost over 5 years of initially feeding infants with eHCF plus LGG was less than that of feeding infants with an eHCF alone (£4229 versus £5136 per patient). Conclusions: First-line management of newly diagnosed infants with IgE-mediated CMPA with eHCF plus LGG instead of an eHCF alone improves outcome, releases healthcare resources for alternative use, reduces the NHS cost of patient management and thereby affords a cost-effective dietetic strategy to the NHS.

[1]  S. Saxena,et al.  Impact of preventive primary care on children’s unplanned hospital admissions: a population-based birth cohort study of UK children 2000–2013 , 2018, BMC Medicine.

[2]  R. Kobayashi,et al.  Cost-effectiveness of using an extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG in managing infants with cow’s milk allergy in the US , 2018, Current medical research and opinion.

[3]  S. Waserman,et al.  IgE-mediated food allergy , 2018, Allergy, Asthma & Clinical Immunology.

[4]  G. Bedogni,et al.  Extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG reduces the occurrence of other allergic manifestations in children with cow's milk allergy: 3‐year randomized controlled trial , 2017, The Journal of allergy and clinical immunology.

[5]  Karl Claxton,et al.  Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal. , 2016, Health economics.

[6]  A. Majeed,et al.  Primary Care Access, Emergency Department Visits, and Unplanned Short Hospitalizations in the UK , 2016, Pediatrics.

[7]  J. Guest,et al.  Relative cost-effectiveness of an extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG in managing infants with cow’s milk allergy in Italy , 2015, ClinicoEconomics and outcomes research : CEOR.

[8]  S. Saxena,et al.  Impact of UK Primary Care Policy Reforms on Short-Stay Unplanned Hospital Admissions for Children With Primary Care–Sensitive Conditions , 2015, The Annals of Family Medicine.

[9]  J. Guest,et al.  Cost-effectiveness of using an extensively hydrolyzed casein formula plus the probiotic Lactobacillus rhamnosus GG compared to an extensively hydrolyzed formula alone or an amino acid formula as first-line dietary management for cow’s milk allergy in the US , 2015, ClinicoEconomics and outcomes research : CEOR.

[10]  H. Gravelle,et al.  Effect of a national primary care pay for performance scheme on emergency hospital admissions for ambulatory care sensitive conditions: controlled longitudinal study , 2014, BMJ : British Medical Journal.

[11]  M. Mckee,et al.  Health services for children in western Europe , 2013, The Lancet.

[12]  B. Niggemann,et al.  Diagnostic approach and management of cow's-milk protein allergy in infants and children: ESPGHAN GI Committee practical guidelines. , 2012, Journal of pediatric gastroenterology and nutrition.

[13]  S. H. Arshad,et al.  Guideline fever: an overview of DRACMA, US NIAID and UK NICE guidelines , 2012, Current opinion in allergy and clinical immunology.

[14]  A. Coruzzo,et al.  Effect of Lactobacillus GG on tolerance acquisition in infants with cow's milk allergy: a randomized trial. , 2012, The Journal of allergy and clinical immunology.

[15]  S. Sicherer.  Epidemiology of food allergy. , 2011, The Journal of allergy and clinical immunology.

[16]  A. Branum,et al.  Food Allergy Among Children in the United States , 2009, Pediatrics.

[17]  R. Wood,et al.  The natural history of IgE-mediated cow's milk allergy. , 2007, The Journal of allergy and clinical immunology.

[18]  A. Holzel.  Allergy in children. , 1977, Nursing times.

[19]  A. Henning,et al.  The natural history of milk allergy in an observational cohort. , 2013, The Journal of allergy and clinical immunology.

[20]  D. Quinton,et al.  Unit Costs of Health and Social Care 2004 , 2004 .

[21]  J. Guest,et al.  Clinicoeconomics and Outcomes Research Dovepress Relative Cost-effectiveness of Using an Extensively Hydrolyzed Casein Formula Containing the Probiotic Lactobacillus Rhamnosus Gg in Managing Infants with Cow's Milk Allergy in Spain , 2022 .

[22]  Berni Canani,et al.  Formula Selection for Management of Children with Cow Milk Allergy Influences the Rate of Acquisition of Tolerance: a Prospective Multicenter Study , 2022 .

[23]  Larry E. Miller,et al.  Clinicoeconomics and Outcomes Research Dovepress Relative Cost-effectiveness of Using an Extensively Hydrolyzed Casein Formula Containing the Probiotic Lactobacillus Rhamnosus Gg in Managing Infants with Cow's Milk Allergy in Poland , 2022 .